Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

First clinical sites approved and actively screening potential participantsRepresents another major milestone in the advancement of IHL-42X ...
Nasdaq

Nyxoah Launches Genio System In U.S. With First Commercial Implants For Sleep Apnea

(RTTNews) - Nyxoah SA (NYXH), a medical technology company specializing in innovative treatments for Obstructive Sleep Apnea (OSA), announced the successful implantation of its Genio system in the ...
Nasdaq

Dario and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide

Dario and GreenKey Join Forces to Target $150 Billion Sleep Apnea Market, Addressing 29 Million Americans with Unmet Needs Through Integrated Chronic Care Solution This collaboration unites Dario's ...
FierceBiotech

Apnimed dreams of IPO to fund launch of sleep apnea pill on FDA's desk

Apnimed is having sweet dreams of an IPO that could fund the planned commercial launch of an obstructive sleep apnea (OSA) therapy that is currently awaiting an FDA approval decision. The therapy, ...
KELOLAND News

Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for ...

CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep ...
The Globe and Mail

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to ...

LITTLETON, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the ...